# RNN 2nd Gen Model Abbott Laboratories Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
May 22, 2017
Deal entry on
May 22, 2017
5.00%Expected margin
100.00% successful of 5 deals
$ 122.53 Last close price
at 02-mar-2021

ABT

Model's trade recommendations No return for period yet

5.52% Annual return

$101.03B Market Cap

β 1.50  

ABT

Model (following trade recommendations)

ABT

Underlying stock

S&P 500

Index
Return for period
1.90%
1.78%
52wk return 2.20%
57.11%
16.82%
52wk Range
62.82—128.23
2000.54—2399.63
Sortino ratio 249.74
Sharpe ratio 2.99
Norm. RMSE 3.36%
Downside risk 0.02%
Volatility 0.00%
  • 1.12 (1.94%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Abbott Laboratories (ABT) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since April 29, 2015.

Market data for ABT model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for ABT.

Model is being retrained on a regular basis.

Float 1733M
P/E 22.17
Shares Outstanding 1746M
% Held by Insiders 0.74%
% Held by Institutions 72.27%
EPS (last reported FY) $2.50
EPS (last reported Q) $0.59
EPS, estimated (last reported Q) $0.58
Total revenues $27 B
Net income $0 B